Delving into the Latest Updates on MAPS Europe B.V. with Synapse

Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder - Long-term follow-up of MDMA-assisted therapy for PTSD

开始日期2022-09-07

申办/合作机构

MAPS Europe B.V.

NCT04030169

/ Completed临床2期

An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Psychotherapy With an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects With Posttraumatic Stress Disorder

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
The main question it aims to answer is: Do two open-label sessions of MDMA-assisted therapy reduce PTSD symptoms?
Participants will receive three non-drug preparatory sessions followed by two sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.

开始日期2020-06-24

申办/合作机构

MAPS Europe B.V.

[+1]

100 项与 MAPS Europe B.V. 相关的临床结果

登录后查看更多信息

0 项与 MAPS Europe B.V. 相关的专利（医药）

登录后查看更多信息

100 项与 MAPS Europe B.V. 相关的药物交易

登录后查看更多信息

100 项与 MAPS Europe B.V. 相关的转化医学

登录后查看更多信息